Spacelabs Medical faces Class I recall; Siemens sounds off on device tax repeal push;

 @FierceMedDev: Next-gen prostate cancer Dx faces skepticism, competition. Story | Follow @FierceMedDev

 @MarkHFierce: Some companies are shedding drug operations to focus more on devices, while BD is adding a (generic) drug arm. Press release | Follow @MarkHFierce

 @DamianFierce: Intuitive Surgical will have its day in court after a judge ruled to allow a patient's suit. News | Follow @DamianFierce

> The FDA put a Class I tag on Spacelabs Medical's recall of its anesthesia workstations, warning that a defect could lead to too much carbon dioxide being delivered to a patient, possibly resulting in injury or death. More

> According to a study from Albuquerque's Mind Research Network, MRI scans can help predict whether felons are likely to commit crimes again by charting brain activity. Article

> Siemens Healthcare North America CEO Greg Sorensen says the recent Democratic support for a medical device tax repeal shows lawmakers are experiencing buyer's remorse over the 2.3% charge. Op-ed

> Somnetics International gained a CE marking for two new devices designed to treat sleep apnea. Release

> Quest Diagnostics ($DGX) is promoting the fact that its clinical genotypic tropism diagnostic test for HIV-1 qualifies under new government guidelines for tests that can assess patients' suitability for a specific class of HIV antiretroviral therapies. Item

> BioDrain Medical has raised some cash to help promote its automated surgical fluid disposal device. Story

> Nanova, a University of Missouri spinout, expects to secure $6 million from Chinese investors toward development of orthopedic, dental and cardiovascular biomedical devices. Story

Biotech News

 @FierceBiotech: Guest post by Lee Feigenbaum on Big Data sheds light on pharma's 'Small Data' problems. Industry Voices | Follow @FierceBiotech

@JohnCFierce: Blessed by Gates, crowdfunding site funnels cash for high-risk R&D. Report | Follow @JohnCFierce

@RyanMFierce: Aastrom sinks after biotech flushes PhIII study for cardio therapy, halves staff. News | Follow @RyanMFierce

> Sarepta's high-noon decision on eteplirsen draws a big biotech crowd. Story

> Little-known Reviva attracts a big angel crowd for $12M CNS round. More

> What's in a cancer drug name? Maybe a $1.5M cash windfall for researchers. Article

Pharma News

@FiercePharma: Pfizer's targeted lung cancer drug Xalkori too expensive, U.K. cost-effectiveness body says. More | Follow @FiercePharma

@EricPFierce: Teva, Samsung face biosimilar realities. The business is not for the "faint of heart," but has great potential. More | Follow @EricPFierce

> Can public health campaigns goose Gardasil and Cervarix sales? More

> NICE nixes Pfizer's targeted lung cancer drug as too pricey. Article

> Novartis sweats Glivec patent verdict in India. Report

Drug Delivery News

@MichaelGFierce: FierceDrugDelivery Special Report: Drug-Delivery Device Combos to Watch. Report | Follow @MichaelGFierce

> FDA approves Novartis' inhaled powder drug for cystic fibrosis infection. Story

> Intarcia enrolls PhIII glucose control study for Type 2 diabetes. Item

> Nanoparticles deliver cancer drug, spare fertility. News

> FDA panel OKs Titan's addiction drug delivery platform. More